Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) and for geographic atrophy secondary to age-related macular degeneration (SAGA) will be presented during the American Society of Retina Specialists (ASRS) 43rd Annual Scientific Meeting being held July 29 to Aug. 2, 2025, in Long Beach, Calif.
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025Participants treated with gildeuretinol in the SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD) showed a slower decline in vision-related quality of life and functional reading scores compared to placebo, demonstrating functional benefit
Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) and geographic atrophy secondary to age-related macular degeneration (SAGA) will be presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held May 4-8 in Salt Lake City.
Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory BoardPreeminent retinal disease expert panel to support Alkeus’ development programs and science
Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) and geographic atrophy secondary to age-related macular degeneration (SAGA) will be presented at the 48th Annual Meeting of the Macula Society being held February 12-15 in Charlotte Harbor, Fla.
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt PatientsCAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years.
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy to prevent blindness in patients with Stargardt disease, during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, ItalyCAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) will be presented at the 12th International FLORetina ICOOR Congress being held December 5-8 in Florence, Italy.
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt DiseaseCAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that gildeuretinol (ALK-001), an investigational oral therapy, has received Rare Pediatric Disease and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of Stargardt disease.
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial OfficerAccomplished Finance and Commercial Leader Brings Extensive Life Sciences Expertise
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function ImprovementCAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate of 15.3% vs. placebo from 6 to 24 months (p=0.047). Gildeuretinol also demonstrated a statistically significant visual function improvement, showing 4.4 fewer letters lost (p=0.031) in low luminance visual acuity (LLVA) over 24 months. Gildeuretinol showed a clinically meaningful trend in slowing GA growth rate of 13.4% from baseline to 24 months (p=0.075), the study’s primary endpoint. A trend toward functional benefit in best corrected visual acuity (BCVA) was demonstrated with 3.3 fewer letters lost (p=0.099).
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in ChicagoResults from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationCAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) demonstrated a reduction of 0.25 sqmm/year vs. placebo (p=0.07) in the primary endpoint of GA lesion growth rate at 24 months. Gildeuretinol demonstrated a statistically significant reduction in the loss of low luminance visual acuity (LLVA) at 24 months (p=0.03). Gildeuretinol showed a favorable safety profile consistent with other studies of gildeuretinol in Stargardt disease. The topline results will be presented as a late breaker at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) during Retina Subspecialty Day on Friday, October 18, in Chicago.
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources OfficerAccomplished cultural transformation leader brings extensive company-building expertise
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEOCAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer and will be responsible for leading the organization’s growth in preparation for commercial launch of its lead asset, gildeuretinol acetate, as a potential treatment for Stargardt disease. Alkeus Co-Founder Leonide Saad, Ph.D., has been named Chief Scientific Officer and will remain an integral part of the company’s continued development of novel treatments for serious diseases of the eye.
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal OfficerBrings over two decades of biopharmaceutical legal, compliance and leadership experience
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9Oral Presentation and Four Posters to Highlight Alkeus’ Progress in Advancing Research to Address Unmet Needs for People Affected by Serious Degenerative Eye Diseases
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical OfficerCAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease ProgressionCAMBRIDGE, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years. In its ongoing TEASE-3 clinical trial in early-stage Stargardt disease, the first three teenage patients enrolled in TEASE-3 and treated with oral gildeuretinol acetate remained asymptomatic and free of disease progression for their treatment duration ranging between two (one patient) and six years (two patients). In the absence of treatment, the patients were projected to begin experiencing vision loss within two years, following the same disease trajectory as that of their respective older siblings with identical genetic mutations who had not been treated with gildeuretinol.
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive Officer, will provide a corporate update and present the latest information on its late-stage investigational therapy to prevent blindness, during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 10, 2024, at 11:30 a.m. PST at The Westin St. Francis Hotel. There will be no live webcast of the presentation.
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt DiseaseSAN FRANCISCO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals today announced positive data from its TEASE-1 study, a randomized, double-masked, placebo-controlled clinical trial investigating the effects of gildeuretinol (ALK-001) in patients with Stargardt disease. Christine Kay, M.D., of Vitreo Retinal Associates Florida, will present the trial results during the 2023 American Academy of Ophthalmology (AAO) Retina Subspecialty Day.
